The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.

European Journal of Haematology
Luigia LucianoGiorgina Specchia

Abstract

Development of the highly selective targeted tyrosine kinase inhibitors (TKIs) has expanded the therapeutic options for chronic myeloid leukemia (CML). Patients undergoing TKI therapy should be closely monitored to ensure that the best therapeutic response and quality of life are achieved, and to control suboptimal responses and adverse events. Despite the high rate of response using current first-line TKIs, treatment failure may still occur, and resistance is considered a challenge in the treatment of patients with CML. The third-generation TKI, ponatinib, is a potent orally bioavailable pan BCR-ABL inhibitor that inhibits both wild-type and mutant BCR-ABL1 kinase, including the "gatekeeper" T315I mutation, which is resistant to all other currently available TKIs. This paper reviews the effectiveness, feasibility, and safety of ponatinib in the real-life clinical management of CML. Potential prognostic factors in identifying patients most likely to benefit from ponatinib treatment will be discussed, and case presentations illustrating situations encountered in real-life clinical practice are described. Ponatinib is effective in patients who have received prior TKIs in clinical studies as well as under real-life conditions. Nev...Continue Reading

References

Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alfonso Quintás-Cardama, Jorge Cortes
Nov 8, 2011·Hematology/oncology Clinics of North America·Elias JabbourJorge Cortes
Nov 7, 2012·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·William H EaglsteinMartin C Robson
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Jun 25, 2014·Mediterranean Journal of Hematology and Infectious Diseases·Lodovico Balducci, Dawn Dolan
Nov 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CastagnettiUNKNOWN GIMEMA CML Working Party
Feb 24, 2015·The Medical Clinics of North America·Charlotte CarlsonMichi Yukawa
Mar 31, 2015·Annals of Hematology·Martin HöglundBengt Simonsson
Apr 29, 2015·Blood·Susanne SausseleUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group
Jan 23, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christine Kujak, Jill M Kolesar
Mar 8, 2016·British Journal of Haematology·Simona SoveriniGiovanni Martinelli
Apr 2, 2016·The Oncologist·Simona SoveriniGiovanni Martinelli
Jun 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hannah BowerTherese M-L Andersson
Sep 24, 2016·Neoplasia : an International Journal for Oncology Research·Roberto LatagliataGiuliana Alimena
Nov 3, 2016·Nature Reviews. Clinical Oncology·Gianantonio RostiMichele Baccarani
Nov 2, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Bin-Qiao WangKe-Qing Shi
Mar 9, 2017·The New England Journal of Medicine·Andreas HochhausUNKNOWN IRIS Investigators
Mar 23, 2017·Nature·Andrew A WylieWilliam R Sellers
Apr 2, 2017·Journal of Cancer Research and Clinical Oncology·Francis J GilesAndreas Hochhaus
Jun 29, 2017·Haematologica·Michele BaccaraniGiuseppe Saglio
Aug 12, 2017·Expert Review of Hematology·Kiran NaqviFarhad Ravandi
Sep 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HochhausUNKNOWN ESMO Guidelines Committee
Oct 4, 2017·Current Cancer Drug Targets·Fulvio MassaroMassimo Breccia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.